CATALAYER NEWS
Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab
Source: Insider Monkey · 2026-03-29
Full article text is available in the Catalayer news terminal.
MORE FROM INSIDER MONKEY
Why Alnylam’s Best Quarter Ever Didn’t Come With a Richer Valuation
2026-07-28
Salesforce’s Agentforce Bet Made It the Dow’s Worst Performer. Is the Market Overreacting?
2026-07-28
RELATED MARKETS
Prediction Markets